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Abstract
The term acute liver failure (ALF) refers to the acute (<26 weeks) and severe worsening in 
liver function associated with encephalopathy in a person with no underlying chronic liver 
disease. ALF constitutes a critical clinical syndrome that is potentially reversible but has a 
very variable prognosis. No specific treatment is available, and liver transplantation (LT) is 
the treatment of choice in many cases. However, the challenge remains of identifying those 
patients with a poor likelihood of spontaneous recovery of liver function and for whom the 
indication and time of LT in order to guarantee survival (based on identification of prognos-
tic factors) need to be established. In Europe, 8% of LT are due to ALF. Although the results 
of LT due to ALF have improved over recent years, they are still far from those seen after 
elective LT.
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1. Introduction
Acute liver failure (ALF) is defined as the presence of acute liver injury, that is, a rise in trans-
aminases at least three times the upper limit of normal, jaundice, and coagulopathy, together 
with the onset of encephalopathy in a person with no previous liver disease [1]. Exceptions 
to this definition include the acute onset of Wilson disease, autoimmune hepatitis, and the 
Budd-Chiari syndrome, as well as reactivation of the hepatitis B virus (HBV) [2].
Though no consensus exists on the severity of the coagulopathy or the encephalopathy 
marking the transition from acute liver injury to ALF, an INR ≥1.5 and any degree of 
encephalopathy are generally accepted [3]. Clinically, ALF is classified according to the 
interval between the onset of jaundice, considered as the initial symptom, and the encepha-
lopathy. The ALF is considered to be hyperacute if the encephalopathy appears within 
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7 days of the jaundice, acute if it appears between 8 and 28 days, and subacute when it 
appears beyond 28 days [4]. The disease is considered chronic if it has a history of more 
than 26 weeks.
Table 1 summarizes the causes of ALF. Worldwide, infection is the most common cause, 
though in developed countries drug-induced hepatic injury is responsible for up to 50% of 
cases. As many as 30% of cases are of unknown etiology [5].
The main causes of death due to ALF are infection and decerebration from cerebral edema. 
The medical management of patients is based on support measures, early identification, and 
treatment of complications until spontaneous recovery of liver function or liver transplanta-
tion (LT) [6].
Establishing the indication for and time of LT in a patient with ALF should be as precise as 
possible in order to avoid, on one hand, unnecessary risks for a recoverable patient and on the 
other an increased likelihood of death associated with a delay in transplantation.
Viral
HAV, HBV, HCV, HEV
CMV, EBV, HSV, VZV, dengue
Pharmacologic/toxic
Paracetamol (acetaminophen)
Idiosyncratic drug reaction
Amanita phalloides
Vascular
Budd-Chiari
Ischemic hepatitis
Pregnancy
Preeclampsia
HELLP
Fatty liver of pregnancy
Others
Wilson disease
Autoimmune hepatitis
Lymphomas and other neoplastic diseases
Hemophagocytic lymphohistiocytosis
Cryptogenic
Table 1. Etiology of the acute liver failure.
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2. Indication for liver transplantation in acute liver failure
Liver transplantation in ALF has represented an inflection point in the survival of affected 
patients, who previously suffered a mortality rate of almost 85% in the pretransplant era [7].
Indicating LT too soon involves the possibility of performing the transplant in patients who 
may still experience spontaneous recovery with complete liver function, thereby adding the 
risks associated with an urgent transplant and lifelong immunosuppression, in addition to the 
waste of a valuable organ. However, delaying the decision to transplant in patients with ALF 
can increase the risk of infection, irreversible brain damage, multiorgan failure, or even death. 
Accordingly, selection of ALF patients who need LT should be based on the early identifica-
tion of factors predicting a poor clinical outcome, as well as application of prognostic models 
combining different parameters. Unfortunately, the prognostic models available have certain 
limitations, low sensitivity and specificity, and worse predictive value than desired [8].
2.1. Predictive factors
The etiology is considered a predictive factor. Around 60% of patients with ALF due to 
paracetamol intoxication, hepatitis A, ischemic hepatitis, or pregnancy may survive with no 
need for transplantation, whereas only 30% of cases with drug-induced liver injury, autoim-
mune hepatitis, and various cases of unknown etiology achieve spontaneous recovery [9].
The duration of symptoms has traditionally had a prognostic value. The subacute presenta-
tion of ALF is associated with a worse prognosis than acute and hyperacute ALF, though 
these differences are probably conditioned by the etiology of the subacute failure [10].
Encephalopathy, although it forms part of the definition of ALF, should also be classified. 
Patients with grades 1–2 encephalopathy have an excellent prognosis, whereas grades 3–4 
encephalopathy is associated with a low likelihood of spontaneous resolution [11] and is thus 
criteria for admission to the intensive care unit, with a recommendation to measure the intra-
cranial pressure as a marker of the preservation of brain perfusion [12]. Coagulopathy, as a 
direct indicator of liver function, is considered to predict the severity. Generally measured 
using the prothrombin time (PT) or the International Normalized Ratio (INR), a PT over 90 s 
or an INR >4 is associated with a mortality rate above 90% [13]. Factor V levels <20% in patients 
younger than 30 years and levels <30% in those older than 30 years indicate a worse prognosis.
The histologic findings have also been proposed as predictors of the outcome and the likeli-
hood of spontaneous recovery. Though some series have related the risk of death with the 
presence of >50% hepatocyte necrosis, the little representativity of the samples together with 
the risk involved in performing a liver biopsy in patients with coagulopathy generally advise 
against routine histologic study in patients with ALF, and nor should the decision to trans-
plant be based on biopsy findings. A liver biopsy could be indicated in cases of diagnostic 
doubt, especially to rule out neoplastic causes, which contraindicate LT [14]. Other factors, 
such as age, body mass index, serum bilirubin, creatinine, hypoglycemia, lactate levels, and 
pH changes, can also be considered determinant.
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All these factors help to identify patients with ALF who have a worse prognosis. Recently, 
the EASL established recommendations for the early transfer to transplant centers of patients 
with ALF if they fulfill the following criteria [15]:
• ALF due to paracetamol or hyperacute causes:
• Arterial pH <7.3 or HCO
3
 <18
• INR >3.0 day 2 or >4 thereafter
• Oliguria and/or elevated creatinine
• Altered level of consciousness
• Hypoglycemia
• Elevated lactate unresponsive to fluid resuscitation
• Non-paracetamol:
• Arterial pH <7.3 or HCO3 <18
• INR >1.8
• Oliguria/renal failure or Na <130 mmol/L
• Encephalopathy, hypoglycemia, or metabolic acidosis
• Bilirubin >300 μmol/L (17.6 mg/dL)
• Shrinking liver size
2.2. Prognostic models
The currently available prognostic models should be applied continuously during the fol-
low-up and clinical management of patients with ALF, even though they are not universally 
accepted or their recommendations established.
In 1989, the King’s College Hospital criteria (KCC) were established (Table 2) [16]. These are 
based on cohort studies and are widely used at the present time. They are based mainly on the 
etiology, differentiating between ALF secondary to paracetamol and ALF of other causes. They 
are highly specific, that is, patients who fulfill these criteria have a high likelihood of death if 
they do not undergo LT. However, their sensitivity is low, as seen from the death of patients 
who do not meet the criteria, especially in patients with causes other than paracetamol [17]. A 
meta-analysis found a specificity of 82% for etiologies other than paracetamol and 92–95% for 
causes related with paracetamol. The sensitivity was about 68%. Both sensitivity and specific-
ity increase if the criteria are applied dynamically [18]. In an attempt to improve the predic-
tive value of the KCC, the measurement of lactate as an indicator of tissue dysfunction and 
failure of hepatic clearance has been added to the criteria in the UK. This is particularly useful 
in cases of paracetamol toxicity. An admission arterial lactate >3.5 or >3 mmol/L after fluid 
resuscitation is a marker of poor prognosis [19, 20].
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The Clichy criteria, established in 1986, also derive from cohort studies in patients with fulmi-
nant hepatitis B (Table 3) [21]. Validation studies found less accuracy than for the KCC, with 
a positive predictive value of 89%, but a negative predictive value of 36%. They are, therefore, 
very deficient for identifying potential survivors without a LT [22].
The MELD score (Table 4), adopted by the United Network for Organ Sharing (UNOS) and 
The Organ Procurement and Transplantation Network (OPTN), has been validated as a pre-
dictor of short-term mortality in patients with hepatic cirrhosis. Retrospective studies have 
shown that the MELD score has a similar predictive value to the KCC for AFL-associated 
mortality [23]. In the USA, the prospective data from the Acute Liver Failure Study Group 
(ALFSG) showed that a MELD >30 in patients with ALF due to paracetamol has a negative 
predictive value of 82%, such that patients with a MELD <30 have a high likelihood of survival 
without a LT and with a slightly lower score in cases not related with paracetamol [24].
AFL due to paracetamol
• Arterial pH <7.3 after resuscitation and 24 h since ingestion
• Three following criteria:
• Hepatic encephalopathy grades 3–4
• Serum creatinine >300 mol/L (3.4 mg(dl)
• INR >6.5
ALF not due to paracetamol
• INR >6.5
• Three out of five following criteria:
• Etiology: indeterminate etiology hepatitis, drug-induced hepatitis
• Age <10 years or >40 years
• Interval jaundice encephalopathy >7 days
• Bilirubin >300 mol/L (17 mg/dl)
• INR >3.5
Table 2. King’s College criteria.
• Confusion or coma (hepatic encephalopathy 3–4)
• Factor V <20% of normal if age <30 years or factor V <30% if age >30 years
Table 3. Clichy criteria.
9.57 × loge(creatinine) + 3.78 × loge(bilirubin) + 11.2 × loge(INR) + 6.43
Table 4. MELD (MELD calculator).
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In an attempt to improve the prognostic accuracy in ALF patients, other indicators of liver 
dysfunction have been suggested, such as measures of hepatic metabolism with markers 
labeled with indocyanine green [25], as well as predictive models of mortality used in other 
clinical situations. The APACHE II system, designed to predict mortality in intensive care 
patients, has also been applied in ALF patients, but no cut point has been set demonstrating 
that it is superior to the KCC and nor can it be applied early on [26].
A prognostic index designed by the ALFSG included variables at the time of presentation of 
the condition, such as bilirubin, encephalopathy grade, INR, phosphorus, and serum levels of 
M30 (a direct marker of hepatocyte apoptosis). Although the prognostic value of this index was 
greater than the KCC and MELD score, measurement of M30 is not generally available [27].
Comparison between these different models, which share some parameters, has found no supe-
riority of one over the others, and no universal recommendations have been established. It is, 
however, accepted that ALF should be strictly assessed at the reception center and, if the patient 
meets the criteria for a poor prognosis, they should be referred as soon as possible to a transplant 
center where the available predictive models can be applied dynamically, mainly the KCC and 
Clichy criteria, to determine the indication for LT. American and European series show that 50% of 
patients admitted with ALF receive a LT [28]. Once the indication for a transplant has been made, 
the patient is included on the active list, in most countries with a higher priority than patients with 
other indications, thus ensuring an early transplant, usually within days of being placed on the list.
If a donor organ becomes available, the situation of the patient should be reassessed by the 
transplant team, in order to identify a likely clear improvement after transplant or else an 
absolute contraindication for transplant, mainly the presence of irreversible brain damage.
3. Outcome of liver transplant in acute liver failure
In Europe LT due to acute or subacute liver failure accounts for some 8% of LT. Patient sur-
vival after LT for this reason is 79, 71, 69 and 61%, at 1, 3, 5 and 10 years, respectively [29]. This 
survival rate is slightly lower during the initial years (first and third) than LT for other reasons 
but then becomes similar. Most deaths occur between the first and third years posttransplant 
due, mainly, to neurologic complications and sepsis [30]. Some centers have reported survival 
rates of up to 86% [31]. Overall survival is probably greatly influenced by patient age, with 
data from the European Transplant Registry showing 1- and 5-year survival of 51 and 42% in 
patients older than 60 years [29].
3.1. Factors influencing the results
Multiple factors have been associated with the outcome of patients who receive a LT due to 
ALF. Three studies [4, 32, 33] have identified a recipient age above 45–50 years as a poor prog-
nostic factor, attributing this to the reduction in physiologic reserve with effect from these 
ages [4]. A body mass index (BMI) >29 was identified in one study [32]. On the other hand, no 
specific factor associated with the severity of the ALF, such as coagulopathy, has been found 
to be associated with a poor prognosis, although the degree of kidney failure, mechanical 
ventilation, and the use of inotropic drugs were found to be predictive factors in these studies. 
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Such donor characteristics as age >60 years, ABO incompatibility [34, 35], and the use of a split 
or small liver have also been related with worse results [18, 36].
Survival has improved greatly over the last decade. This is the result of better management of 
ALF patients, leading to a lower incidence of pretransplant complications (e.g., renal failure, 
respiratory problems, sepsis), a lower grade of encephalopathy, and the use of more isogroup 
grafts. Identification of prognostic factors as well as the creation of transplant indication crite-
ria like the Clichy [37] or King’s College [16] criteria has also contributed to this improvement. 
The earlier indication for transplant, which in turn contributes to the use of more compatible 
organs and the patient receiving the transplant in better conditions, has been the foundation 
for the improvement in results over recent years.
The rapid localization of organs for transplant in ALF patients is an important factor that has 
also contributed greatly to the better results. In countries like Spain, with a high donation rate, 
it proves relatively easy to find a compatible organ fairly quickly, with 50% of these patients 
receiving a transplant within 24 h of becoming active on the waiting list, while the mean time 
to transplant is 40 h. In Spain this has resulted in only around 7% of ALF patients dying while 
still on the waiting list compared with 30% in the USA [38].
Thus, the optimal selection of candidates for transplant plus the identification of poor prog-
nostic factors and the exclusion of those patients who will not benefit from LT due to their 
situation have contributed to the improved results. The development of extracorporeal bio-
artificial systems, improved organ procurement, and the use of organs from living donors can 
all contribute to future improvements.
4. Conclusion
Acute liver failure is a potentially severe clinical condition that is associated with a high rate 
of mortality. Selection of those patients who will benefit from a liver transplant should be 
based on the early identification of prognostic factors. Survival of patients who receive a 
transplant due to ALF has improved over recent years, though it is still somewhat lower than 
that of patients who receive a LT for other reasons.
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